Krishan Batra, MD
Addiction Psychiatry · Odessa, FLNPI 1518021336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 136 payments — averaging $72.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$932
- Axsome Therapeutics, Inc.$866
- Supernus Pharmaceuticals, Inc.$840
- plus $4K from 15 others
What the payments were for
- Speaking & faculty fees$5005%
- Food & beverage$9,36294%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $1,456 |
| Teva Pharmaceuticals USA, Inc. | 14 | $1,133 |
| AbbVie(2 entities) | 25 | $1,055 |
| Otsuka America Pharmaceutical, Inc. | 8 | $932 |
| Axsome Therapeutics, Inc. | 7 | $866 |
| Supernus Pharmaceuticals, Inc. | 12 | $840 |
| Alkermes, Inc. | 9 | $701 |
| Neurocrine Biosciences, Inc. | 6 | $488 |
| Sunovion Pharmaceuticals Inc. | 5 | $389 |
| Indivior Inc. | 3 | $255 |
| Corium, LLC | 6 | $232 |
| Vanda Pharmaceuticals Inc. | 2 | $229 |
| Jazz Pharmaceuticals Inc. | 2 | $228 |
| E.r. Squibb & Sons, L.L.C. | 3 | $224 |
| Johnson & Johnson | 4 | $204 |
| Idorsia Pharmaceuticals US Inc | 4 | $185 |
| Neos Therapeutics, LP | 1 | $124 |
| Ironshore Pharmaceuticals Inc. | 2 | $123 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $106 |
| Braeburn Inc. | 1 | $96 |
| Lundbeck LLC | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,407
- CAPLYTA$1,076
- Auvelity$744
- REXULTI$611
- Austedo XR$588
- VRAYLAR$578
- ARISTADA$464
- INGREZZA$379
- LATUDA$371
- SUNOSI$350
- AUSTEDO$325
- QELBREE$243
- ABILIFY MAINTENA$239
- SUBLOCADE$231
- Fanapt$229
- UZEDY$133
- QUVIVIQ$125
- Adzenys XR-ODT$124
- ABILIFY ASIMTUFII$123
- Azstarys$122
How this compares
$9,917 in reported general payments places this provider in the 80th percentile of 29 addiction psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $122,978 |
| Invega SustennaPaliperidone Palmitate | 14 | $45,264 |
| VraylarCariprazine Hcl | 18 | $32,467 |
| RexultiBrexpiprazole | 16 | $25,285 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $7,312 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 19 | $5,373 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $5,265 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $5,117 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $2,546 |
| Olanzapine | 57 | $1,106 |
| Duloxetine Hcl | 40 | $788 |
| Bupropion XlBupropion Hcl | 41 | $728 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $725 |
| Hydroxyzine Hcl | 27 | $692 |
| Doxepin Hcl | 24 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $488 | $122,97815 claims |
| Johnson & JohnsonInvega Sustenna | $204 | $45,26414 claims |
| AbbVieVraylar | $1,055 | $32,46718 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $932 | $25,28516 claims |
| Indivior Inc.Suboxone | $255 | $5,26511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 29 addiction psychiatry providers in Florida.
Other addiction psychiatry in Odessa
- Raul RodriguezDelray Beach$31K
- Jason FieldsNew Port Richey$26K
- Edward BariasJupiter$21K
- Mary SheehanTampa$16K
- Aldo MoralesFort Lauderdale$13K
- Lawrence WeinsteinSt Petersburg$6K
- Syed ZaidiPinellas Park$5K
- Vincence DillonPensacola$2K
- Curtis PhillipsDelray Beach$2K
- Zaheer AslamFort Myers$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.